# Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.

> PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33638863-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33638863-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33638863-abaloparatide-v1.json
- Content SHA-256: `1c90a5c559bfc96b3c09f58ac23cfde4f6b4b1c8ad1fec14bea7ddf5993ad9ee`

## Claims and source pins

### Headline

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

### Summary

PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

### Paragraph 1

PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`](#source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e))

## Sources

<a id="source-pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e"></a>
- **Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. · retained source version 1:2024-03-31:current:7d0404213a0e8fa90c0adc92e9249edc2eae1da988a7357d53aeffa63c7c4166** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33638863/) (`pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33638863-abaloparatide-v1.json SHA-256: 1c90a5c559bfc96b3c09f58ac23cfde4f6b4b1c8ad1fec14bea7ddf5993ad9ee.